key: cord-0717485-2qcuygax
authors: Grima, A.; Murison, K.; Simmons, A.; Tuite, A.; Fisman, D.
title: Relative Virulence of SARS-CoV-2 Among Vaccinated and Unvaccinated Individuals Hospitalized with SARS-CoV-2
date: 2022-02-17
journal: nan
DOI: 10.1101/2022.02.15.22271016
sha: 71ba1a268a161814f641b7b472e3a5df0da0ef8b
doc_id: 717485
cord_uid: 2qcuygax

Background: The rapid development of safe and effective vaccines against the SARS-CoV-2 virus has been a singular scientific achievement. Confounding due to health seeking behaviours and differential testing by vaccination status may bias analyses towards an apparent increase in infection severity following vaccination. We sought to determine whether risks of intensive care unit (ICU) admission and death were diminished significantly by vaccination, even in individuals for whom vaccination failed to prevent hospitalization. Methods: We used data from Ontario, Canadas Case and Contact Management database, merged to a provincial vaccination dataset (COVaxON) to create a time-matched cohort of individuals who were hospitalized with SARS-CoV-2 infection. Each vaccinated individual was matched to up to five unvaccinated individuals based on test date of positive SARS-CoV-2 infection. Risk of ICU admission and death were evaluated using multivariable conditional logistic regression. Unmatched exploratory analyses were performed to identify sources of heterogeneity in vaccine effects. Results: In 20,064 individuals (3,353 vaccinated and 16,711 unvaccinated) hospitalized with infection due to SARS-CoV-2 between January 1st, 2021 and January 5th, 2022, vaccination with 1, 2, or 3 doses significantly reduced the risk of ICU admission and death. An inverse dose-response relationship was observed between vaccine doses received and both outcomes (adjusted odds ratio (aOR) for ICU admission per additional dose: 0.66, 95% CI 0.62 to 0.71; aOR for death per additional dose: 0.78, 95% CI 0.72 to 0.84). The reduction in risk was greater for ICU admission than for death (P for heterogeneity <0.05), but no significant differences in risk were seen based on infecting variant of concern (VOC). Interpretation: We identified a decrease in the risk of ICU admission and death in vaccinated individuals compared to unvaccinated, time-matched controls, even when vaccines failed to prevent infection sufficiently severe to cause hospitalization. Even with diminished efficacy of vaccines against infection with novel VOCs, vaccines remain an important tool for reduction of ICU admission and mortality.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 17, 2022 The global pandemic of SARS-CoV-2 has sickened hundreds of millions of people, and 56 killed millions (1). The rapid development of safe and effective vaccines against the virus has 57 been a singular scientific achievement and has likely prevented many more illnesses and deaths 58 (2) (3) (4) . However, the ongoing emergence of novel viral variants remains a challenge, with 59 reduced protection against infection seen with the B.1.529 (Omicron) variant that emerged in 60 autumn 2021 (5) , though vaccines seem to continue preventing severe illness resulting in 61 hospitalization, intensive care admission, and death. Indeed, the effectiveness of vaccination for 62 prevention of severe outcomes may reflect two different effects, which may be difficult to 63 disentangle: (i) prevention of infection, and (ii) prevention of severe outcomes even when 64 vaccination does not prevent infection. Studies may be further complicated by factors such as 65 decreased propensity to test vaccinated individuals with mild symptoms of respiratory illness, 66 which could produce biases that result in increased apparent severity of infection following 67 vaccination. 68 We have previously evaluated the effectiveness of SARS-COV-2 vaccines in the 69 Canadian province of Ontario to prevent infection (6) . However, vaccines that result in 70 attenuation of severity, even among individuals in whom they failed to protect against infection, 71 would be of considerable value to vaccinated individuals and to the wider community by limiting 72 consumption of scarce critical care resources. We sought to study the impact of prior 73 vaccination on severity of illness among individuals admitted to hospital with SARS-COV-2 in 74 Ontario, Canada, as a study limited to hospitalized individuals should limit biases introduced by 75 differential testing according to disease severity and vaccination status. As both the propensity 76 to receive vaccination and the dominant viral variant of concern (VOC) has varied over the 77 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 17, 2022. ;  course of the pandemic in Ontario, we used a time-matched cohort to evaluate the adjusted risk 78 of intensive care unit (ICU) admission and death in vaccinated and unvaccinated individuals, 79 with identically timed infection, admitted to Ontario hospitals. Our primary objective was to 80 determine whether the risks of ICU admission and death were diminished significantly by 81 vaccination among individuals whose vaccination failed to prevent hospitalization. We also 82 performed exploratory analyses to evaluate whether protective effects were modified by 83 individuals' characteristics, or by infecting viral variant. 84 85 86 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Methods 87

We created a time-matched cohort of individuals who were hospitalized due to SARS-90

CoV-2 infection between January 1 st , 2021 and January 5 th , 2022. Individuals who had received 91 one, two, or three doses of a SARS-COV-2 vaccine were included as exposed and were matched 92 to unvaccinated individuals based on the test date for SARS-CoV-2. Each vaccinated individual 93 was matched with up to five unvaccinated individuals, acting as controls (7). We identified 94 vaccinated and unvaccinated SARS-CoV-2 cases in the Province's Case and Contact 95 Management (CCM) system, as described elsewhere (8, 9) . 96

We included only cases with a unique "pseudo-health card number", permitting linkage 97 with the provincial vaccination COVaxON database (9) , which provided information on dose 98 administration, dates, and vaccines used. We considered individuals to be vaccinated 14 days or 99 more after vaccine dose administration (10) . We used date of positive testing as a surrogate for 100 onset of infection; when individuals had a test date <14 days from a dose of vaccine, they were 101 considered not to be protected by that dose. There have been several waves of the SARS-CoV-2 pandemic in Ontario, with different 109 infecting variants prevalent for each. Initial waves were driven by the Wuhan variant, then waves 110 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We used our matched cohort to calculate the risk of ICU admission and death among 122 those hospitalized due to SARS-COV-2 using conditional logistic regression models. The models 123 were specified a priori to adjust for age category (treated as a nine-level ordinal variable), sex, 124 healthcare worker status, long-term care residence, comorbidity, and infecting variant. Vaccine 125 status was treated as a four-level nominal variable (zero, one, two, or three doses) where zero 126 doses was used as the referent. Due to the rarity of deaths in healthcare workers, healthcare 127 worker status was not included in models evaluating risk of death. 128

We also performed exploratory restriction analyses in which vaccinated and unvaccinated 129 cases were limited to a single infecting variant (non-VOC, N501Y+ VOC, Delta VOC, or 130

Omicron VOC) to evaluate modification of observed effects of vaccination of ICU admission 131 and death by infecting variant. As conditional logistic regression models failed to converge for 132 some of these models, we modeled the effect of vaccination using unmatched logistic regression 133 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 17, 2022. ; https://doi.org/10.1101/2022.02.15.22271016 doi: medRxiv preprint models, with time trend modeled as a cubic trend function. Lastly, we investigated heterogeneity 134 in the adjusted odds ratios (aORs) for ICU admission and death using meta-analytic techniques 135 (i.e., graphically using forest plots, and statistically using the meta-analytic Q statistic). The 136 study was conducted in accordance with the STROBE guidelines for observational research (13) , 137 and received ethics approval from the Research Ethics Board at the University of Toronto. 138 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) We fit two conditional logistic regression models to assess the risk of being admitted to 147 the ICU and the risk of death in hospitalized individuals ( We also performed an exploratory subgroup analysis on the odds of ICU admission and 159 death stratified by the infecting variant. Heterogeneity in the aORs for ICU admission and death 160 is shown in Figure 2 . There was no significant heterogeneity between variants within each 161 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. and selection bias, inasmuch as vaccinated individuals may be less likely to be tested for mild 175 symptoms of infection but may be more likely to be tested overall. 176

The significant protective effects of vaccination against ICU admission and death were 177 seen for both the N501Y+ and Delta variants in exploratory restriction analyses. While we did 178 not identify significant protection against the Omicron variant in restriction analyses, this likely 179 reflects low statistical power due to recent Omicron emergence. We found no evidence for 180 heterogeneity in effect according to infecting variant. We did, however, identify greater 181 protection against ICU admission than against death with vaccines. It is possible that this may 182 relate to the protective effect seen with long-term care residence, adjusted for other covariates, 183 but the increased risk of death associated with this factor. 184

Protection against infection and symptomatic infection has declined with the emergence 185 of novel variants of concern, most notably the Omicron variant (5, (14) (15) (16) (17) . While recent data 186 suggest that booster doses of mRNA vaccines substantially restore vaccine efficacy (16, 17) , our 187 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 17, 2022. ; https://doi.org/10.1101/2022.02.15.22271016 doi: medRxiv preprint analysis shows that prior partial vaccination can provide benefits to individuals and health 188 systems even when vaccines fail to prevent infection, or even hospitalization, and remains an 189 important pillar of the public health response to the SARS-CoV-2 pandemic. 190

The effects we demonstrate here are not unique to SARS-CoV-2 and we have previously 191 identified similar effects with prior pneumococcal and influenza vaccination (18, 19) . As with 192 that earlier work, an important limitation here is the inability to ensure that the effects we 193 observe are not at least in part due to residual confounding. This is a potential limitation of any 194 cohort study; and is one that will be the focus of future work. The relatively recent emergence of 195 the Omicron variant, and the lags associated with critical illness and death, results in the lack of 196 statistical power to estimate Omicron-specific protections as noted above. Unfortunately, 197 ongoing high rates of SARS-CoV-2 hospitalizations, critical illnesses, and deaths in Ontario 198 mean that we will be able to address this potential limitation in the months ahead. The authors with to thank the staff at Public Health Ontario and Ontario's public health units for 207 collecting, sequencing, analyzing, and providing access to the data used for this analysis. 208 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 17, 2022. ; https://doi.org/10.1101/2022.02.15.22271016 doi: medRxiv preprint The analysis is stratified by outcome, with results for death in the upper rows, and ICU admission below. NOTE: CI, confidence interval; ICU, intensive care unit; I-V, contribution of within-stratum variance to overall variance; n501, N501Y-positive variant; VOC, variant of concern.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 17, 2022. ;

Unprecedented achievement': who received the first billion COVID vaccinations? Nature

Estimated number of deaths directly averted in people 60 years and older as a result of COVID-19 vaccination in the WHO European Region

Vaccinations Against COVID-19 May Have Averted Up To 140,000 Deaths In The United States. Health Aff (Millwood)

Report 48 -The value of vaccine booster doses to mitigate the global impact of the Omicron SARS-CoV-2 variant

COVID-19 case age distribution: correction for differential testing by age

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario

COVID-19 Fully Vaccinated Status in Ontario

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes

Comparative complete scheme and booster effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infections with SARS-CoV-2 Omicron (BA.1) and Delta (B.1.617.2) variants

Influenza vaccination and risk of mortality among adults hospitalized with community-acquired pneumonia

Prior pneumococcal